ABT-737

AdipoGen Life Sciences
Product Code: SYN-1001

CodeSizePrice
SYN-1001-M100100 mgEnquire
Quantity:
SYN-1001-M0011 mg£80.00
Quantity:
SYN-1001-M0055 mg£115.00
Quantity:
SYN-1001-M01010 mg£174.00
Quantity:
SYN-1001-M05050 mg£631.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
-20°C

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
ABT737
Appearance:
Solid.
CAS:
852808-04-9
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H303, H317, H333
InChi:
InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1
InChiKey:
HPLNQCPCUACXLM-PGUFJCEWSA-N
Long Description:
Chemical. CAS: 852808-04-9. Formula: C42H45ClN6O5S2. MW: 813.4. ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumors, and produces cures in a high percentage of the mice. ABT-737 binds to Bcl-2, Bcl-xL and Bcl-w with very high affinities (Ki <1 nM) and also shows a very high specificity over Mcl-1 and A1.
Molecular Formula:
C42H45ClN6O5S2
Molecular Weight:
813.4
Package Type:
Plastic Vial
Precautions:
P280, P301, P312, P304, P312, P302, P352, P333, P313
Product Description:
ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumors, and produces cures in a high percentage of the mice. ABT-737 binds to Bcl-2, Bcl-xL and Bcl-w with very high affinities (Ki <1 nM) and also shows a very high specificity over Mcl-1 and A1.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

An inhibitor of Bcl-2 family proteins induces regression of solid tumours: T. Oltersdorf, et al.; Nature 435, 677 (2005) | Synthesis and biological activities of new di- and trimeric quinoline derivatives: S. Broch, et al.; Bioorg. Med. Chem. 18, 7132 (2010) | Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL: B.E. Sleebs, et al.; J. Med. Chem. 56, 5514 (2013)